← Patent-cliff monitor small molecule LAZCLUZE LAZERTINIB MESYLATE
Loss of exclusivity August 2041 latest FDA-listed patent expiry
Drug detail Brand name LAZCLUZE Active ingredient LAZERTINIB MESYLATE Strength EQ 240MG BASE Dosage form TABLET Route ORAL Modality Small molecule FDA approval August 2024 Marketing status RX
Listed patents Patent Expires Type 11850248 August 2041 use U-3985 12138351 April 2041 product 11879013 May 2040 use U-3985 12599606 May 2040 use U-4511 12318390 April 2038 product 11453656 April 2038 substance, product 11981659 April 2038 use U-3985 9593098 October 2035 substance, product
Regulatory exclusivity Code Expires NCE August 2029
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.